These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 1862786

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
    Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE.
    Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
    Collins ED, Horton T, Reinke K, Amass L, Nunes EV.
    J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
    [Abstract] [Full Text] [Related]

  • 6. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts.
    Nava F, Caldiroli E, Premi S, Lucchini A.
    J Addict Dis; 2006 Mar; 25(2):9-16. PubMed ID: 16785214
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Heroin detoxification with a single high dose of buprenorphine.
    Kutz I, Reznik V.
    Isr J Psychiatry Relat Sci; 2002 Mar; 39(2):113-9. PubMed ID: 12227226
    [Abstract] [Full Text] [Related]

  • 9. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS.
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance.
    Calsyn DA, Malcy JA, Saxon AJ.
    J Subst Abuse Treat; 2006 Mar; 30(2):159-63. PubMed ID: 16490679
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients.
    Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De Chiara M, Corrado F, Cocchi L, Cozzolino E.
    J Subst Abuse Treat; 2006 Jul; 31(1):3-7. PubMed ID: 16814005
    [Abstract] [Full Text] [Related]

  • 14. Clonidine and opiate receptor antagonists in the treatment of heroin addiction.
    Gerra G, Marcato A, Caccavari R, Fontanesi B, Delsignore R, Fertonani G, Avanzini P, Rustichelli P, Passeri M.
    J Subst Abuse Treat; 1995 Jul; 12(1):35-41. PubMed ID: 7752296
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Buprenorphine dosing regime in the management of out-patient heroin withdrawal.
    Lintzeris N.
    Drug Alcohol Rev; 2002 Mar; 21(1):39-45. PubMed ID: 12189003
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Regarding naltrexone for probationers and parolees.
    Stancliff S.
    J Subst Abuse Treat; 2007 Mar; 32(2):217-8; author reply 218-9. PubMed ID: 17306730
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.